Exhibit 10.4
AGREEMENT
This Agreement (“Agreement”) is made and entered into as of the 3 day of February 2013 (“Effective Date”), by and between:
Tel Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Hashomer, Israel, 52621, represented by its authorized representatives(“THM”); and
Prof. Dror Harats,ID no. 054496641 of Ramat Gan, Israel (“Prof. Harats”); and
Vascular Biogenics Ltd., Company no. 51-289976-6, a private company duly incorporated under the laws of the State of Israel having its registered office at 6 Yoni Netanyahu Street, Or Yehuda, Israel, 60376, represented by its authorized representatives (“VBL” or the “Company”).
| WHEREAS: | THM declares that it is a private company, whose purpose is to promote the welfare of the Sheba Medical Center (the “Hospital”); and |
| WHEREAS: | THM declares that at the request of the Hospital and the Fund, as defined below, THM undertook to act as the operational body of the Hospital and Fund, with respect to promotion, development and commercialization of intellectual property deriving from inventions of Hospital’s and/or Fund’s employees;and |
| WHEREAS: | Prof. Harats has been an employee of the Hospital and/or the Fund since 1995; and |
| WHEREAS: | VBL was established in 1999; and |
| WHEREAS: | The Hospital and the Fund have claims regarding the ownership of certain inventions and patent rights of the Company, developed in part by Prof. Harats, and certain other inventors defined herein as Inventors and VBL disagrees, denies and refutes all such claims in their entirety; and |
| WHEREAS: | THM, on behalf of the Hospital, and the Fund reached an agreement resolving the above dispute as stipulated and set forth hereunder; |
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the parties hereby agree and stipulate as follows:
| 1. | PREAMBLE AND DEFINITIONS |
| | 1.1 | The Preamble to this Agreement as well as all the Agreement’s appendices constitutes an integral part thereof. |
| | 1.2 | The descriptive headings of this Agreement are inserted for convenience only and shall not be considered a part or affect the interpretation of this Agreement. |
| | 1.3 | In addition to terms defined elsewhere in this Agreement or its appendices, the following terms shall have the meaning ascribed to them hereinafter: |
| | 1.3.1 | “Affiliate” shall mean, with respect to a Party, any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only, “control” of another person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, “control” shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or more of the outstanding share capital or other ownership interest of the other organization or entity, or (ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the organization or other entity. |
| | 1.3.2 | The “Fund” shall mean Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA). |
| | 1.3.3 | “Intellectual Property” shall mean any or all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including without limitation: (i) all United States, Israeli, international and foreign patents and applications therefor (including PCT), including any and all reissues, divisionals, patent of division applications, renewals, extensions, continuations, and continuity applications thereof, whether or not related to such divisionals, patent of division application, renewals, extensions, continuations or continuity applications through one or more intervening applications, and any patent or application acquired as a result of prevailing in any interference proceeding (the “Patent Rights”); (ii) all inventions (whether patentable or not), invention disclosures, trade secrets, proprietary information, know-how, technology, technical data and customer lists, and all documentation in any form or media relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world; (iv) all databases and data collections and all rights therein throughout the world; (v) all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefore throughout the world; and (vi) all domain names, uniform resource locators, and other names and locators associated with the internet. |
2
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | 1.3.4 | The “Inventors” – As specifically detailed inAppendix A attached hereto and constituting an integral part thereof. Such Inventors are inventors who have been employed by Sheba. |
| | 1.3.5 | The “Company’s IP”: shall mean (i) the Intellectual Property owned, registered or controlled by the Company which is specified inAppendix B attached hereto;(ii)any continuations in part of the Company’s IP listed inAppendixB; and (iii) any Intellectual Property to the extent that it is dated prior to the date hereof and incorporates and /or based upon the patents specified in Appendix B and/or any Intellectual Property to the extent that it is dated prior to the date hereof and that the patents listed in Appendix B are based thereon. |
| | 1.3.6 | The “Products” shall mean any product, agent, process, or service device which is covered by or is produced or manufactured or rendered (as the case may be) using a process or method covered by the Company’s IP. |
| | 1.3.7 | “Net Sales” shall mean the total amount invoiced by or on behalf of VBL or any of its Affiliates or Licensees, in connection with the sale of a Product after deduction of: (i) value added taxes, excise and sales taxes, or other similar taxes imposed on such sales (excluding income or franchise taxes of any kind) (ii) amounts credited by a credit note; and (iii) reasonable quantities for promotional purposes, and compassionate uses; provided however that the Company doesn’t receive any consideration relating thereto; |
| | | For the purpose hereof: (a) with respect to sales which are not at arm’s length and/or are not according to the current market conditions for such a sale, the term “Net Sales” shall mean the total amount that would have been paid in an arm’s length sale made according to the current market conditions for such sale or according to market conditions for sale of products similar to the Products; (b) with respect to sales by VBL and/or a Licensee, as applicable, to any Affiliate, the term, “Net Sales” shall mean the higher of: (i) “Net Sales”, as defined above in paragraph (a) and (ii) the total amount invoiced by such affiliated entity on resale to an independent third party purchaser and (c) with respect to sales for non-monetary consideration for any Products, “Net Sales” shall be calculated based on the higher of: (i) “Net Sales”, as defined in paragraph (a) above; and (ii) the total amount invoiced by the party acquiring the Products in such transaction in each case, after deducting the amounts permitted above, to the extent applicable. |
| | 1.3.8 | “License” shall mean the grant of any right or license and any agreement executed, by VBL to or with any entity, permitting any use of Company’s IP (or any part thereof) including for the development and/or manufacture and/or marketing and/or distribution and/or sale of Company’s IP, and/or the Products and the term “Licensee” shall be construed accordingly. |
3
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | 1.3.9 | “License Fee” shall mean the consideration of any type or nature, received (for the removal of doubt, whether received before or after the First Commercial Sale in any country) by the Company in return for or in connection with the grant of Licences or the grant of an option for a Licence, and excluding amounts received by the Company which are included under the definition of “Net Sales” based on sales of the Products by Licensees, in respect of which the Company has paid royalties to THM according to this Agreement or otherwise constitute payment upon Exit Event according to this Agreement; License Fee shall include any lump sums, revenues from License Fees, milestone payments, etc. but shall specifically exclude reimbursement for research and development and patent related expenses/reimbursement for payments specifically committed to cover costs reasonably and actually incurred by Company under, and in accordance with detailed budgets and workplans included in, license agreements with Licensees. Any consideration other than cash payment shall be calculated based on the fair market value of such consideration assuming an arm’s length transaction made in the ordinary course of business. Upon request, the Company shall provide THM with all documents and figures reasonably necessary in order to verify Company’s compliance with this clause. |
| | 1.3.10 | “First Commercial Sale” shall mean with respect to any Product in any country, the first commercial sale of the Product in such country after FDA Approval for marketing or equivalent approval in such country has been obtained if such approval is required. |
| 2. | PARTIES’ DECLARATIONS AND UNDERTAKINGS |
| | 2.1 | THM undertakes and covenants as follows: |
| | 2.1.1 | Subject to the performance of the Company’s obligations hereunder, THM hereby irrevocably confirms on behalf of the Hospital and the Fund that such entities, or anyone on their behalf do not have any further right to receive any payment, compensation, funds or securities from Prof. Dror Harats and/or from the Company (including its officers, directors, shareholders, employees, affiliates, successors and assigns, whether current, past or in the future) and/or the Inventors (the “Released Parties”) deriving from any claim of ownership in the Company’s IP, and hereby irrevocably waives and releases acquits and forever discharges each of the Released Parties from any and all rights, claims, demands, commitments, actions, charges, complaints, promises, agreements, controversies, debts, counterclaims, suits, causes of action, damages, liabilities, obligations, costs and expenses of every kind and nature whatsoever, known or unknown, past, present or future, at law or in equity, contingent or otherwise (collectively, a “Claim”), such parties, including their successors and/or assigns, may have, as a result of a claim of ownership in the Company’s IP now or in the future, (“Released Matters”). |
4
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | Notwithstanding anything to the contrary in this Agreement, it is hereby clarified that the above waiver specified in this clause 2.1.1, applies and relates only to any part of the Company’s IP which is created, conceived and/or developed by the Inventors and not to Company’s IP or any part thereof or any other Intellectual Property owned by the Company which is created, conceived and/or developed by any other inventors, employees, agents and/or contractors on behalf of the Company to the extent they are not listed inAppendix A. |
| | 2.1.2 | 2.1.3 Prof Harats shall be entitled to serve as Chief Executive Officer and member of the Board of Directors of the Company to develop intellectual property that constitutes continuations in part of the Company IP and subject to duly filing the required reports to THM and to the Ministry of Health, to receive compensation in shares and in cash, without any further claim by the Releasing Parties. |
| | 2.2 | Each party hereby represents and warrants that: (a) it has the power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and that the execution, delivery and performance by it of this Agreement and its compliance with the terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) any other right or obligation provided under any other agreement or obligation that it has with any third party; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; (b) the Agreement is a binding enforceable obligation of such Party; and (c) no consent, approval, authorization order, filing, registration, or qualification of or with any court, governmental authority, or third person is required to be made or obtained by a party in connection with the execution and delivery of this Agreement or the consummation by a party of the transactions contemplated hereby, which has not been received. |
5
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
VBL undertakes that any License granted by it shall be subject to the following terms:
| | 3.1 | The License is granted according to a written appropriate and binding agreement. The material terms of each License will be disclosed orally by the legal counsel of VBL to the head of THM prior to the execution of any License agreement. Following execution of any such agreement, the Company will either (i) provide a copy of such agreement to THM; or (ii) if the provision of a copy of such agreement is not allowed under the terms thereof, disclose to THM’s attorney and its accounting firm the material terms of such agreement, including without limitation, any terms that have bearing upon the consideration payable to THM hereunder. Such disclosure to THM’s attorney or CPA shall be subject to their execution of a non disclosure agreement. The Company shall verify that the License includes terms that will allow the disclosure of the material terms thereof to THM or to a third party to be designated by THM, and shall comply with such terms. |
| | 3.2 | The License is being granted in a bona fide arms-length commercial transaction. |
| | 3.3 | Non monetary consideration, if any, shall be valued as set forth in this Agreement. |
| | 4.1 | VBL undertakes to pay THM the following amounts on a Product-by-Product and country-by-country basis until the later to occur of: (i) the last to expire or terminate of any of the Patent Rights covering such Product in such country; or (ii) fifteen (15) years from the date of the First Commercial Sale of such Product in such country: |
| | 4.1.1 | Royalties. VBL shall pay THM 1% (one percent) of Net Sales by or on behalf of VBL or any Affiliate or any Licensee (the “Royalties”). |
| | 4.1.2 | Licensing Consideration. VBL shall pay THM 2% (two percent) of any License Fee received by VBL (the“Licensing Consideration”). |
| | 4.2 | The amounts payable to THM under clause 4.1 shall be paid as follows: |
| | 4.2.1 | Royalties, as specified in sub-clause 4.1.1 in connection with Net Sales by VBL and its Affiliate, shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which the respective sale took place, commencing on the first quarter where the First Commercial Sale took place. Royalties in connection with Net Sales by a Licensee shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which VBL receives payment on account of Net Sales. |
| | 4.2.2 | Licensing Consideration, as specified in sub-clause 4.1.2 shall be paid within 30 (thirty) business days from receipt of any License Fee by the VBL. |
6
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | 4.3 | Consideration from Exit. Upon the closing of each Exit Event, as defined bellow, THM shall be entitled to receive from the Company 1% (one percent) of any and all consideration received by the Company and/or its shareholders as a result of or in connection with such Exit Event (“Consideration From Exit”). |
Consideration from Exit Event under clause 4.3 shall be paid in cash within 15 (fifteen) days from the closing of the Exit Events defined above. To the extent that the applicable Exit Event is an IPO or the consideration is in kind and not cash payment then the Company may pay the Consideration From Exit within 12 months following the closing of the respective Exit Event.
“Exit Event” means any of the following events: (i) the closing of the merger or consolidation of VBL into or with other corporation or the acquisition of the Company thereby, excluding a transaction following which VBL is the surviving corporation and the shareholders of VBL prior to the transaction constitute the majority of the shareholders following such transaction; or (ii) the closing of the sale of all or substantially all of the assets of VBL or all or substantially all of its issued and outstanding share capital or (iii) the closing of an Initial Public Offering (“IPO”). Notwithstanding the above, in all cases, a transaction with a wholly owned subsidiary or a transaction effected for the purpose of changing the domicile or structure of VBL shall not be deemed an Exit Event.
| | 4.4. | Payment obligations under clause 4 shall expire if the payment to THM upon or prior to such Exit Event (but not by way of payment of Royalties under clause 4.1.1) is or exceeds NIS100 million. In addition, at any time following the execution hereof the Company, its assignees or successors shall be entitled to terminate the payment obligations under clause 4 by payment to THM of the amount of NIS100 million after deduction of any amount previously received by THM, provided that such amounts were not received by THM as Royalties under clause 4.1.1. It is hereby clarified that termination of the obligation to pay Consideration From Exit, according to this clause 4.4 which did not exceed NIS 100 million, does not and shall not derogate from Company’s obligation for payments as specified in clauses 4.1.1 and 4.1.2 until an aggregate payment of NIS 100 million has been made (but not by way of payment of Royalties payable under clause 4.1.1). |
| | 4.5 | All amounts set forth herein are inclusive of any and all taxes. The Company (or the escrow agent, if applicable) shall be entitled to deduct at source or withhold from any amount payable hereunder any tax amount applicable to THM in connection with each payment. |
| | 4.6 | The Company shall report in writing to THM immediately upon execution of an agreement relating to the First Commercial Sale and upon the occurrence of such first Commercial Sale. The Company shall specify in such report the date of execution of such agreement and the date of the First Commercial Sale according to the agreement. |
| | 4.7 | In calculating Net Sales and License Fee, all amounts shall be expressed in US Dollars and any amount received or invoiced in a currency other than US Dollars shall be translated into US Dollars, for the purposes of calculation, in accordance with the exchange rate between the US Dollar and such currency on the date of such receipt or invoice, as the case may be. |
7
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | 4.8 | The Company shall provide THM with the following written reports: (a) a detailed quarterly report, commencing with the first calendar quarter in which any Net Sales are made, or License Fee received, in a form reasonably acceptable to THM, signed by the chief financial officer of VBL, specifying all amounts payable to THM under this clause 4 in respect of the previous quarter to which the report refers. Such report shall include: (i) the sales made by the Company, Affiliates and Licensees with a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products sold and; (ii) License Fee with a breakdown according to identity of Licensees, countries, the currency of the payment and date of receipt thereof; and (iii) deductions applicable, as provided in the definition of “Net Sales”; (b) a detailed report within twenty one (21) days of an Exit Event specifying the nature of the Exit Event, the consideration to be received by the Company or its shareholders in connection with such Exit Event and all other substantial terms and details of such Exit Event and enclose to the report any agreement executed in connection with such Exit Event immediately following the execution thereof; and (iv) any other matter, data and documents reasonably required by THM and existing with VBL in order to calculate and/or verify the amounts payable hereunder; and (c)Within four months after the end of each fiscal year, the Company will provide THM with a detailed report, certified by VBL’s Chairman of the Board and by its independent auditor, stating all amounts due to THM pursuant to this clause 4 in the reported year including relevant invoices issued and all invoices and all payments received by the Company with respect to details specified in the above reports; 21 days prior to an Exit Event he material terms of such Exit will be disclosed orally by the legal counsel of VBL to the head of THM. |
| | 4.9 | The Company shall keep and shall cause Licensees to keep complete, accurate and correct books of account and records consistent with sound business and accounting principles and practices. |
| | 4.10 | Following the First Commercial Sale, THM shall be entitled to appoint an independent auditor selected by it to inspect, after coordination with VBL and during VBL’s regular business hours, all records, and documents of VBL as may contain information bearing upon the amounts payable to THM under this clause 4. The Company shall take all steps necessary so that all such books of account, records and other documentation of VBL and its Licensees and Affiliates are available for inspection as aforesaid for each of the Company and its Licensees and Affiliates. The cost of such auditing shall be borne by VBL if the audit uncovers an underreporting of the corresponding amounts owed to THM by more than ten percent (10%). Otherwise, such costs and expenses shall be borne by THM. VBL shall remedy such discrepancy and pay (i) the shortfall within thirty (30) days of the date of discovery; and (ii) interest thereon at the rate of 4% above the London Interbank Offered Rate (LIBOR) applicable to a 12 month USD deposit, as such rate shall be in effect on each Disbursement Date. The Interest shall be compounded annually and computed on the basis of a 360 day year. |
8
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | 4.11 | Upon THM’s request but not more than once every six months, the Company shall provide THM with a progress report specifying the following details, as updated from the last report: (i) the activities the Company conducted for the development of Products; and (ii) sales and marketing efforts. |
| | 5.1 | VBL undertakes to indemnify and hold harmless THM, the Fund, the Hospital, the State of Israel, and their employees, representatives, agents and contractors (the “THM Beneficiaries”) against and from any loss, liability, claims, damages or expenses of whatever kind or nature incurred by or imposed upon the THM Beneficiaries, to the extent arising out of or resulting from (i) the use and/or exploitation of the Company’s IP or any use of any products incorporating the Company’s IP or any part thereof and/or manufactured or developed based upon the Company’s IP; and (ii) to the extent that it is based on a claim that the Company’s IP, the Products or other material produced or developed or marketed by or on behalf of VBL or any of its Affiliates or Licensee infringes any third party’s intellectual property rights including copyright, trade secret, patent, trademark (a“THM Claim”). |
| | 5.3 | The following mechanism shall apply to anyTHM Claim pursuant to clause 5.1. If any THM Beneficiary receives notice of anyTHM Claim, suchTHM Beneficiary shall, as promptly as is reasonably possible, give VBL notice of suchTHM Claim. The failure to give such notice promptly shall relieve VBL of any indemnification obligation it may have hereunder to the extent such failure diminishes its ability to respond to or to defend the Beneficiary against suchTHM Claim. VBL shall exclusively assume the defence or represent the interests of the THM Beneficiary in respect of suchTHM Claim, that shall include the right to select and direct legal counsel and other consultants to appear in proceedings on behalf of the THM Beneficiary and to propose, accept or reject offers of settlement, all at its sole cost and discretion. |
| | 5.4 | VBL, at its own expense, shall maintain insurance in an amount consistent with industry standards which provides VBL adequate coverage for (i) performing clinical studies of the Product in humans, (ii) product liability and (iii) commercial sales of applicable and relevant Products. |
In the event that the Company decides to abandon its patents in all applicable jurisdictions in connection with its intent to stop its entire business activities of either of its two business units, then with respect to such Patent Rights that are included in the Company’s IP, the Company will inform THM (“VBL Notice”) of its intention prior to the abandonment of any such Patent Rights.
9
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
THM shall have the right to continue to support and maintain any such Patent Rights provided that it notifies VBL of its intention within 30 days following the receipt of VBL Notice, and provided further that within 60 days following the notice by THM, the parties reach an agreement for the assignment or license of such Patent Rights to THM. The parties shall negotiate such agreement in good faith. The parties further agree that such agreement shall provide VBL with payments similar to those set forth in clause 4 and that any such agreement shall be subject to any limitations and restrictions imposed by applicable third parties, including without limitation, the Office of the Chief Scientist and shall be subject to the assumption by THM of any repayment obligations thereto. THM right hereunder shall lapse and be of no further force and effect, in the event that THM fails to timely respond to VBL Notice, indicates that it is not interested in the Patent Rights or otherwise the parties fail to reach an agreement as aforesaid during the 90 day period.
| | 7.1 | Law and Venue. All disputes arising in connection with this Agreement shall be settled amicably in the first instance. If amicable settlement cannot be reached by the Parties within 15 (fifteen) days from the day either Party approached the other Parties specifying the essence of the dispute, the dispute shall be settled by 1 (one) arbitrator. If the Parties fail to reach an agreement on the nomination of the arbitrator within 30 (thirty) days of the date when the claimant’s request for arbitration was communicated by the other Parties, the appointment shall be made by the Head of the Israel Bar. The arbitration will be conducted in Tel Aviv, Israel. The Parties shall be entitled to seek interim measures of protection in the form of pre-award attachment of assets or injunctive relief. The tribunal shall issue a reasoned award. Such award may grant any relief appropriate under applicable law including without limitation declaratory relief and/or specific performance. As part of its award the tribunal may award attorneys fees and costs to the prevailing party. The award of the arbitrator shall be final and binding upon the Parties, but subject to appeal, with respect to the disputes so submitted and the costs of such arbitration. The law that shall apply shall be the statutes and laws of the State of Israel. |
| | 7.2 | Use of Names. The Company shall not use the names of the State Of Israel, Hospital, the Fund and/or THM and/or their employees, representatives, agents and contractors in any manner or in any publication including commercial publicity, without the prior written consent of THM. |
| | 7.3 | Assignment. This Agreement shall be personal to the parties and therefore the Parties may not assign any of their rights or obligations hereunder without the prior written consent of the other party. Notwithstanding the aforementioned, THM shall be entitled to assign the right to receive payments under this Agreement to any association and/or organization and or company that was established in connection with or for the benefit of the Hospital. In addition, VBL may, without the consent of THM, assign this Agreement and the rights, obligations and interests of VBL, in whole, to any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger or consolidation of VBL with or into such corporation, provided that any such assignee agrees in writing to be bound by all the terms of this Agreement. |
10
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | 7.4 | Notices. Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) upon personal delivery (ii) upon facsimile transmission (receipt of which has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit, postage prepaid, return receipt requested, if sent by Registered Mail and addressed to the address of the parties first above stated or in accordance with such other address information as the party to receive notice may provide in writing to the other party in accordance with the above notice provisions. Any notice given by any other method will be deemed to have been duly served upon receipt thereof. |
| | 7.5 | Waivers. No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either Party shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any further or other exercise thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with others and as often and in such order as each party may deem expedient. |
| | 7.6 | Entire Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of the parties with respect to its subject matter. No oral or prior written statements or representations not incorporated herein shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified except in a writing signed by both parties. |
| | 7.7 | Confidentiality. Each party undertakes to the other party that all confidential information disclosed by a party to the other party hereunder or as a result of this Agreement, including the terms and conditions set forth herein, will be kept in the strictest confidence and will not, without the prior written consent of the disclosing party, be used by the receiving party or be disclosed to, or discussed with, any third party whatsoever. The above undertaking of confidentiality will not apply to information which: (i) is in the public domain at the time of disclosure; or (ii) subsequently becomes part of the public domain, except by breach by the receiving party of its obligations, or (iii) is received from a third party who is not under an obligation of confidentiality to the disclosing party. VBL may disclose, on a confidential basis, the terms of this Agreement to its Board of Directors, shareholders, potential investors, acquirers or licensees in the process of due diligence reviews of its contracted obligations, assets and undertakings. |
| | 7.8 | THM hereby declares that Sheba’s management reached an understanding with the management of Tel Aviv University (“TAU”), that as between the Hospital and TAU, inventions of TAU professors who work as medical doctors for Sheba such as Prof. Dror Charats, Prof. Shoenfeld and Prof. Gerge Jacob, shall belong to Sheba. |
11
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
[Remainder of the Page was left intentionally blank]
12
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the undersigned hereby warrants and represents that it has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement.
| | | | | | | | | | |
| Tel Hashomer - Medical Research, | | | | | | Vascular Biogenics Ltd. |
| Infrastructure and Services Ltd. | | | | | | |
| | | | | |
| By: | | [Illegible] | | | | | | By: | | /s/ Dror Harats |
| | | | |
/s/ Dror Harats Prof. Dror Harats | | | | | | | | |
| | | | |
| Approved and Acknowledged | | | | | | | | |
| | | | |
[Illegible] The Government of Israel By the Ministry of Health | | | | | | | | |
13
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
Appendix A
INVENTORS
1. Prof. Dror Harats
2. Shoenfeld Yehuda
3. George Jacob
4. Halperin Gideon – up to 2003
5. Bloom Nira
6. Greenberger Shoshana
7. Tal Reshef
8. Peled Michael
| * | detailed list of inventions is provided underAppendix B. |
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
Appendix B’ up to 3 Feb 2013
| | | | | | | | | | | | | | | | |
METHODS AND COMPOSITIONS FOR ENHANCING TARGETING OF VIRAL VECTORS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
| | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
ISOLATED POLYNUCLEOTIDES AND NUCLEIC ACID CONSTRUCTS FOR DIRECTING EXPRESSION OF A GENE-OF-INTEREST IN CELLS |
Our Ref | | Country | | Earliest Priority | | Entry
Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
| | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | | | | | | | |
52423 | | PCT | | 19-Oct-2010 | | | | 12/10/2011 | | | | 3182.041PC01 | | Pending | | |
| | | | | | | | | | | | | | | | |
TREATMENT WITH VB-201 |
Our Ref | | Country | | Earliest Priority | | Entry
Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
50378 | | PCT | | 05-Jan-2010
61/292,226 | | | | 05-Jan-2011
IL2011/000012 | | Publ. Date: 14-Jul-2011
Publ. #: WO2011/083469 | | 3182.018PC05 | | Expired | | YACOV Niva; BREITBART
Eyal; MENDEL Itzhak; FEIGE Erez; COHEN Yael |
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
PAF-LIKE HOMOLOGS AND USES THEREOF |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
44504 | | PCT | | 16-Oct-2007
60/960,846 | | | | 05-Oct-2008
IL2008/001315 | | Publ. Date: 23-Apr-2009
Publ. #: WO2009/050692 | | | | Expired | | YACOV Niva; BREITBART
Eyal; MENDEL Itzhak |
48215 | | Israel
NP | | 16-Oct-2007
60/960,846 | | 15-Apr-2010 | | 05-Oct-2008
205144 | | | | 3182.019IL01 | | Aban | | YACOV Niva; BREITBART
Eyal; MENDEL Itzhak |
48216 | | USA
NP | | 16-Oct-2007
60/960,846 | | 15-Apr-2010 | | 05-Oct-2008
12/738,097 | | | | 3182.0190001 | | Aban | | YACOV Niva; BREITBART
Eyal; MENDEL Itzhak |
48217 | | Europe
NP | | 16-Oct-2007
60/960,846 | | 14-May-2010 | | 05-Oct-2008
08808113.8 | | | | 3182.019EP01 | | Aban | | YACOV Niva; BREITBART
Eyal; MENDEL Itzhak |
| | | | | | | | | | | | | | | | |
IMPROVED SYNTHESIS OF OXIDIZED PHOSPHOLIPIDS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
3
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
28367 | | PCT | | 09-Jul-2004
60/586,219 | | | | 10-Jul-2005
IL2005/000735 | | Publ. Date: 19-Jan-2006
Publ. #: WO2006/006161 | | | | Expired | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33799 | | Israel
NP | | 09-Jul-2004
60/586,219 | | 09-Jan-2007 | | 10-Jul-2005 | | 1-Mar-2012
180628 | | 3182.020IL00 | | GRANTED | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
50430 | | Israel
DIV | | 09-Jul-2004
60/586,219 | | 17-Mar-2011 | | 10-Jul-2005
211795 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
50431 | | Israel
DIV | | 09-Jul-2004
60/586,219 | | 17-Mar-2011 | | 10-Jul-2005
211796 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33793 | | Europe
NP | | 09-Jul-2004
60/586,219 | | 09-Feb-2007 | | 10-Jul-2005
05758938.4 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33793 Div | | Europe
Div | | 09-Jul-2004
60/586,219 | | Oct 2012 | | 10-Jul-2005 | | | | 3182.020EP10 | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33793 Div | | Europe
Div | | 09-Jul-2004
60/586,219 | | Oct 2012 | | 10-Jul-2005
12179533.0 | | | | 3182.020EP20 | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
39643 | | Hong Kong
NP | | 09-Jul-2004
60/586,219 | | 31-May-2007 | | 10-Jul-2005
07105789.7 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33795 | | Canada
NP | | 09-Jul-2004
60/586,219 | | 09-Jan-2007 | | 10-Jul-2005
2,573,396 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
4
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
33796 | | Japan
NP | | 09-Jul-2004
60/586,219 | | 09-Jan-2007 | | 10-Jul-2005
2007-519983 | | 24-Jun-2011
4,767,948 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
48896 | | Japan
DIV | | 09-Jul-2004
60/586,219 | | 21-May-2010 | | 10-Jul-2005
2010-116964 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33797 | | Republic of Korea
NP | | 09-Jul-2004
60/586,219 | | 09-Feb-2007 | | 10-Jul-2005
2007-7003288 | | 9-Nov-2012
10-1201935 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33798 | | China
NP | | 09-Jul-2004
60/586,219 | | 28-Feb-2007 | | 10-Jul-2005
200580029218.9 | | 3-Aug-2011
200580029218.9 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
48018 | | China
DIV | | 09-Jul-2004
60/586,219 | | 11-Feb-2010 | | 10-Jul-2005
201010128184.1 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
33801 | | Russian Federation
NP | | 09-Jul-2004
60/586,219 | | 09-Feb-2007 | | 10-Jul-2005
2007105097 | | 20-Sep-2010
2399626 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33802 | | Mexico
NP | | 09-Jul-2004
60/586,219 | | 08-Jan-2007 | | 10-Jul-2005
MX/a/2007/000361 | | 17-Mar-2011
284830 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33803 | | Australia
DIV | | 09-Jul-2004
60/586,219 | | 09-Jan-2007 | | 10-Jul-2005
2007200090 | | 2007200090
5 Jan 2012 | | 3182.020AU00 | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
50536 | | Mexico
DIV | | 09-Jul-2004
60/586,219 | | 14-Jan-2011 | | 10-Jul-2005
MX/a/2011/000630 | | 3 Sep 2012
303011 | | | | Granetd | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
5
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
33804 | | New Zealand
NP | | 09-Jul-2004
60/586,219 | | 09-Feb-2007 | | 10-Jul-2005
553147 | | 06-Nov-2010
553147 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
48999 | | New Zealand
DIV | | 09-Jul-2004
60/586,219 | | 29-Jun-2010 | | 10-Jul-2005
586503 | | 10 Oct 2011
586503 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
33805 | | South Africa
NP | | 09-Jul-2004
60/586,219 | | | | 10-Jul-2005
2007/01178 | | 25-Sep-2008
2007/01178 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
| | | | | | | | | | | | | | | | |
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
02/23345 | | USA
CIP | | 17-Nov-2000
60/248,582 | | | | 01-May-2002
10/135,447 | | 27-Jun-2006
7,067,649 | | | | Granted | | HARATS Dror; BREITBART
Eyal; BLOOM Nira |
28786 | | USA
DIV | | 17-Nov-2000
60/248,582 | | 29-Oct-2004 | | 01-May-2002
10/975,619 | | 25-Aug-2009
7,579,327 | | | | Granted | | HARATS Dror; BREITBART
Eyal; BLOOM Nira |
45023 | | USA
DIV | | 17-Nov-2000
60/248,582 | | 03-Jun-2009 | | 01-May-2002
12/457,200 | | | | | | Pending | | HARATS Dror; BREITBART
Eyal; BLOOM Nira |
50926 | | USA
DIV | | 17-Nov-2000
60/248,582 | | 27-Apr-2011 | | 01-May-2002
13/094,900 | | | | | | Pending | | HARATS Dror; BREITBART
Eyal; BLOOM Nira |
53777 | | USA
DIV | | 17-Nov-2000
60/248,582 | | 24-April
2012 | | 01-May-2002
13/454,171 | | | | 3182.0350004 | | Pending | | HARATS Dror; BREITBART
Eyal; BLOOM Nira |
6
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
25974 | | PCT | | 01-May-2002
10/135,447 | | | | 30-Apr-2003
IL03/00347 | | Publ. Date: 13-Nov-2003
Publ. #: WO03/093409 | | | | Expired | | HARATS
Dror |
28650 | | Singapore
NP | | 01-May-2002
10/135,447 | | 01-Nov-2004 | | 30-Apr-2003
200406381-4 | | 30-May-2008
107841 [WO 03/093409] | | | | Granted | | HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira |
28655 | | South Africa
NP | | 01-May-2002
10/135,447 | | 05-Nov-2004 | | 30-Apr-2003
2004/8989 | | 26-Jul-2006
2004/8989 | | | | Granted | | HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
28646 | | Japan
NP | | 01-May-2002
10/135,447 | | 01-Nov-2004 | | 30-Apr-2003
2004-501545 | | | | | | Abandoned | | HARATS
Dror |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
28651 | | Canada
NP | | 01-May-2002
10/135,447 | | 01-Nov-2004 | | 30-Apr-2003
2,483,996 | | | | | | Abandoned | | HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira |
28652 | | Mexico
NP | | 01-May-2002
10/135,447 | | 28-Oct-2004 | | 30-Apr-2003
PA/a/2004/010711 | | | | | | Abandoned | | HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira |
[* * *] | | | | | | | | | | | | | | | | |
7
��
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
COMBINED TREATMENT UTILIZING VB-201
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
50379 | | PCT | | 05-Jan-2010
61/292,226 | | | | 05-Jan-2011
IL2011/000010 | | Publ. Date: 14-Jul-2011
Publ. #: WO2011/083467 | | | | Expired | | YACOV Niva; BREITBART
Eyal; COHEN Yael |
| | US
NP | | 05-Jan-2010
61/292,226 | | 5-July 2012 | | 05-Jan-2011
13/520,713 | | | | 3182.0160005 | | Pending | | YACOV Niva; BREITBART
Eyal; COHEN Yael |
| | EP
NP | | 05-Jan-2010
61/292,226 | | 1-Aug 2012 | | | | | | 3182.016EP05 | | Pending | | YACOV Niva; BREITBART
Eyal; COHEN Yael |
| | JP
NP | | 05-Jan-2010
61/292,226 | | 4-July 2012 | | | | | | 3182.016JP05 | | Pending | | YACOV Niva; BREITBART
Eyal; COHEN Yael |
| | | | | | | | | | | | | | | | |
POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA |
Our
Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
41795 | | PCT | | 31-Jul-2006
60/834,157 | | | | 31-Jul-2007
IL2007/000959 | | Publ. Date: 07-Feb-2008
Publ. #: WO/2008/015675 | | | | Expired | | TAL Reshef; BREITBART Eyal;
BANGIO Livnat |
45501 | | China
NP | | 31-Jul-2006
60/834,157 | | 26-Mar-2009 | | 31-Jul-2007
200780035863.0 | | 8-Aug 2012
ZL20078003 5863.0 | | 3182.040CN01 | | Granted | | TAL Reshef; BREITBART Eyal;
BANGIO Livnat |
8
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
54283 | | China
Div | | 31-Jul-2006
60/834,157 | | 26-June-2012 | | 31-Jul-2007
201210210646.3 | | | | 3182.040CN11 | | Pending | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
45495 | | USA
NP | | 31-Jul-2006
60/834,157 | | 02-Feb-2009 | | 31-Jul-2007
12/309,856 | | | | | | Abandoned | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
51521 | | USA
DIV | | 31-Jul-2006
60/834,157 | | 20-Jun-2011 | | 31-Jul-2007
13/163,776 | | | | | | Pending | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
45496 | | Israel
NP | | 31-Jul-2006
60/834,157 | | 29-Jan-2009 | | 31-Jul-2007
196792 | | | | | | Pending | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
45499 | | Australia
NP | | 31-Jul-2006
60/834,157 | | 02-Feb-2009 | | 31-Jul-2007
2007280017 | | 26-July 2012
2007280017 | | 3182.040AU01 | | Granted | | TAL Reshef; BREITBART Eyal;
BANGIO Livnat |
54370 | | Australia
Div | | 31-Jul-2006
60/834,157 | | 12-July 2012 | | 31-Jul-2007
2012204128 | | | | 3182.040AU11 | | Pending | | TAL Reshef; BREITBART Eyal;
BANGIO Livnat |
45500 | | Japan
NP | | 31-Jul-2006
60/834,157 | | 02-Feb-2009 | | 31-Jul-2007
2009-522416 | | | | | | Pending | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
45502 | | Republic of Korea
NP | | 31-Jul-2006
60/834,157 | | 27-Feb-2009 | | 31-Jul-2007
2009-7004288 | | | | | | Abandoned | | TAL Reshef; BREITBART Eyal;
BANGIO Livnat |
9
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
45503 | | Mexico
NP | | 31-Jul-2006
60/834,157 | | 29-Jan-2009 | | 31-Jul-2007
MX/a/2009/001157 | | | | | | Pending | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
45504 | | New Zealand
NP | | 31-Jul-2006
60/834,157 | | 26-Jan-2009 | | 31-Jul-2007
574410 | | 9 July 2012
574410 | | 3182.040NZ01 | | Granted | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
45505 | | South Africa
NP | | 31-Jul-2006
60/834,157 | | 26-Jan-2009 | | 31-Jul-2007
2009/00581 | | 31-Mar-2010
2009/00581 | | | | Granted | | TAL Reshef; BREITBART
Eyal; BANGIO Livnat |
45506 | | Singapore
NP | | 31-Jul-2006
60/834,157 | | 30-Jan-2009 | | 31-Jul-2007
200900642-0 | | 30-Jun-2011
149616[WO2008/015675] | | | | Granted | | TAL Reshef; BREITBART Eyal;
BANGIO Livnat |
| | | | | | | | | | | | | | | | |
TREATMENT WITH VB-201 |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
50377 | | PCT | | 05-Jan-2010
61/292,226 | | | | 05-Jan-2011
IL2011/000008 | | Publ. Date: 14-Jul-2011
Publ. #: WO2011/083465 | | | | Expired | | YACOV Niva; BREITBART
Eyal; MENDEL Itzhak; SHER
Naamit; COHEN Yael |
| | US NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.0170005 | | Pending | | |
| | AU NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017AU05 | | Pending | | |
10
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | CANADA
NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017CA05 | | Pending | | |
| | China
NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017CN05 | | Pending | | |
| | HK
NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017HK05 | | Pending | | |
| | EP NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017EP05 | | Pending | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | Japan
NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017JP05 | | Pending | | |
| | South Korea
NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017KR05 | | Pending | | |
| | MX
NP | | 05-Jan-2010
61/292,226 | | June 2012 | | 05-Jan-2011 | | | | 3182.017MX05 | | Pending | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
11
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
ANTI-ANGIOGENIC ADENOVIRUS VECTOR SUITABLE FOR CLINICAL APPLICATIONS AND METHODS FOR PRODUCTION THEREOF
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL PREPARATIONS GENERATED THEREBY |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
49684 | | PCT | | 12-Jan-2010
61/294,158 | | | | 12-Jan-2011
IB2011/050137 | | Publ. Date: 21-Jul-2011
Publ. #: WO2011/086509 | | | | Expired | | BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit |
| | US NP | | 12-Jan-2010
61/294,158 | | June 2012 | | 12-Jan-2011 | | | | 3182.0330001 | | Pending | | BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit |
| | EP NP | | 12-Jan-2010
61/294,158 | | June 2012 | | 12-Jan-2011 | | | | 3182.033EP01 | | Pending | | BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit |
[* * *] | | | | | | | | | | | | | | | | |
| | JP NP | | 12-Jan-2010
61/294,158 | | June 2012 | | 12-Jan-2011 | | | | 3182.033JP01 | | Pending | | BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit |
[* * *] | | | | | | | | | | | | | | | | |
12
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
IMMUNOMODULATION (IMMUNIZATION AND TOLERANCE) OF APO-E DEFICIENT MICE WITH 1 HEXADECINYL 2-5’ OXOPENTYL PHOSPHATIDYCHLOLINE (2-5 ALLE-ALDEHYDE LECITIN ETHER) SUPPRESSES EARLY ATHEROGENESIS
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
01/22753 | | PCT | | 24-Nov-2000
60/252,574 | | | | 22-Nov-2001
IL01/01080 | | Publ. Date: 30-May-2002
Publ. #: WO02/41827 | | | | Expired | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26035 | | Europe
NP | | 22-Nov-2000
60/252,574 | | 15-May-2003 | | 22-Nov-2001
01997274.4 | | | | | | Pending | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
52529 | | EP Div | | 22-Nov-2000
60/252,574 | | 17-Nov 2011 | | 22-Nov-2001
11189562.9 | | | | 3182.021EP11 | | Pending | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
27265 | | Hong Kong
NP | | 24-Nov-2000
60/252,574 | | 12-Dec-2003 | | 22-Nov-2001
03109096.1 | | | | | | Pending | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26036 | | Israel
NP | | 22-Nov-2000
60/252,574 | | 20-May-2003 | | 22-Nov-2001
156015 | | 10-May-2008
156015 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
32434 | | Israel
DIV | | 24-Nov-2000
60/252,574 | | 20-Jul-2006 | | 22-Nov-2001
176976 | | 1-Dec 2012
176976 | | 3182.021IL11 | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26037 | | India
NP | | 22-Nov-2000
60/252,574 | | 22-May-2003 | | 22-Nov-2001
796/CHENP/2003 | | 19-Sep-2008
223638 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
13
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
26039 | | Canada
NP | | 22-Nov-2000
60/252,574 | | 22-May-2003 | | 22-Nov-2001
2,429,817 | | | | 3182.021CA01 | | Pending | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26040 | | Australia
NP | | 22-Nov-2000
60/252,574 | | 23-May-2003 | | 22-Nov-2001
2002218461 | | 21-Dec-2006
2002218461 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26041 | | Japan
NP | | 22-Nov-2000
60/252,574 | | 23-May-2003 | | 22-Nov-2001
2002-544008 | | 01-Aug-2008
4,162,486 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
44299 | | Japan
DIV | | 24-Nov-2000
60/252,574 | | 10-Jun-2008 | | 22-Nov-2001
2008-151301 | | 25 May 2012
5001906 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26042 | | China
NP | | 22-Nov-2000
60/252,574 | | 22-Jul-2003 | | 22-Nov-2001
01822215.3 | | 06-Jan-2010
ZL01822215.3 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26043 | | Republic of Korea
NP | | 22-Nov-2000
60/252,574 | | 24-May-2003 | | 22-Nov-2001
2003-7006991 | | 17-Oct-2008
865142 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
26044 | | Mexico
NP | | 22-Nov-2000
60/252,574 | | 22-May-2003 | | 22-Nov-2001
PA/a/2003/004517 | | 02-Sep-2009
269738 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
46494 | | Mexico
DIV | | 24-Nov-2000
60/252,574 | | 12-Jun-2009 | | 22-Nov-2001
MX/a/2009/006365 | | 2 December 2011
293020 | | 3182.021MX11 | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN Gideon |
14
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
36194 | | USA
CIP | | 17-Nov-2000
60/248,582 | | | | 30-Apr-2007
11/790,992 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
43177 | | PCT | | 30-Apr-2007
11/790,992 | | | | 27-Apr-2008
IL2008/000543 | | Publ. Date: 06-Nov-2008
Publ. #: WO2008/132729 | | | | Expired | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART
Eyal; BANGIO Livnat;
PELED Michael |
47030 | | Europe
NP | | 30-Apr-2007
11/790,992 | | 27-Nov-2009 | | 27-Apr-2008
08738245.3 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
48882 | | Hong Kong
NP | | 30-Apr-2007
11/790,992 | | 11-Jun-2010 | | 27-Apr-2008
10105838.3 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47031 | | Japan
NP | | 30-Apr-2007
11/790,992 | | 30-Oct-2009 | | 27-Apr-2008
2010-505002 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47032 | | Canada
NP | | 30-Apr-2007
11/790,992 | | 27-Oct-2009 | | 27-Apr-2008
2,685,394 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47033 | | China
NP | | 30-Apr-2007
11/790,992 | | 30-Dec-2009 | | 27-Apr-2008
200880022935.2 | | | | 3182.039CN01 | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
15
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
47034 | | Australia
NP | | 30-Apr-2007
11/790,992 | | 27-Nov-2009 | | 27-Apr-2008
2008243817 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47035 | | Republic of Korea
NP | | 30-Apr-2007
11/790,992 | | 18-Nov-2009 | | 27-Apr-2008
2009-7024041 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
[* * *] | | | | | | | | | | | | | | | | |
47037 | | Israel
NP | | 30-Apr-2007
11/790,992 | | 26-Oct-2009 | | 27-Apr-2008
201760 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47038 | | Mexico
NP | | 30-Apr-2007
11/790,992 | | 29-Oct-2009 | | 27-Apr-2008
MX/a/2009/011750 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47039 | | New Zealand
NP | | 30-Apr-2007
11/790,992 | | 27-Nov-2009 | | 27-Apr-2008
581511 | | 5 June 2012
581511 | | 3182.039NZ01 | | Granetd | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47040 | | South Africa
NP | | 30-Apr-2007
11/790,992 | | 25-Nov-2009 | | 27-Apr-2008
2009/08331 | | 29-Dec-2010
2009/08331 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
47041 | | Singapore
NP | | 30-Apr-2007
11/790,992 | | 30-Oct-2009 | | 27-Apr-2008
200907209-1 | | 15 May 2012
156740 | | 3182.039SG01 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael |
16
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
THE EFFECT OF MUCOSAL TOLERANCE WITH LIPID IPOPROTEIN AND PROTEIN ANTIGENS ON ATHEROSCLEROSIS IN LDL-RECEPTOR DEFICIENT MICE
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
METHODS EMPLOYING AND COMPOSITIONS CONTAINING PLAQUE ASSOCIATED MOLECULES FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
01/23033 | | PCT | | 04-Jan-2001
60/259,512 | | | | 03-Jan-2002
IL02/00005 | | Publ. Date: 11-Jul-2002
Publ. #: WO02/053092 | | | | Expired | | HARATS Dror; GEORGE
Jacob |
26046 | | Israel
NP | | 04-Jan-2001
60/259,512 | | 03-Jul-2003 | | 03-Jan-2002
156770 | | | | | | Allowed | | HARATS Dror; GEORGE
Jacob |
26047 | | India
NP | | 04-Jan-2001
60/259,512 | | 04-Jul-2003 | �� | 03-Jan-2002
1044/CHENP/2003 | | 19-Sep-2008
223640 | | | | Granted | | HARATS Dror; GEORGE
Jacob |
26048 | | USA
NP | | 04-Jan-2001
60/259,512 | | 02-Jul-2003 | | 03-Jan-2002
10/451,370 | | 09-Oct-2007
7,279,459 | | | | Granted | | HARATS Dror; GEORGE
Jacob |
26050 | | Australia
NP | | 04-Jan-2001
60/259,512 | | 11-Jul-2003 | | 03-Jan-2002
2002225301 | | 03-Mar-2006
2002225301 | | | | Granted | | HARATS Dror; GEORGE
Jacob |
26051 | | Japan
NP | | 04-Jan-2001
60/259,512 | | 03-Jul-2003 | | 03-Jan-2002
2002-554043 | | 26-Sep-2008
4,191,997 | | | | Granted | | HARATS Dror; GEORGE
Jacob |
26052 | | China
NP | | 04-Jan-2001
60/259,512 | | 04-Sep-2003 | | 03-Jan-2002
02805950.6 | | | | | | Pending | | HARATS Dror; GEORGE
Jacob |
17
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
26054 | | Mexico
NP | | 04-Jan-2001
60/259,512 | | 01-Jun-2003 | | 03-Jan-2002
PA/a/2003/006043 | | 17-Mar-2009
265173 | | | | Granted | | HARATS Dror; GEORGE
Jacob |
26045 | | Europe
NP | | 04-Jan-2001
60/259,512 | | 18-Jul-2003 | | 03-Jan-2002
02715682.7 | | | | | | Abandoned | | HARATS Dror; GEORGE
Jacob |
27463 | | Hong Kong
NP | | 04-Jan-2001
60/259,512 | | 28-Jan-2004 | | 03-Jan-2002
04100565.1 | | | | | | Abandoned | | HARATS Dror; GEORGE
Jacob |
26049 | | Canada
NP | | 04-Jan-2001
60/259,512 | | 03-Jul-2003 | | 03-Jan-2002
2,433,781 | | | | | | Abandoned | | HARATS Dror; GEORGE
Jacob |
[* * *] | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
FORMULATIONS AND DOSAGE FORMS OF CI-201 AND RELATED COMPOUNDS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | PCT | | Sept. 1, 2011
61/529,989 | | | | Aug. 31, 2012
PCT/US2012/053533 | | | | 3182.013PC01 | | Pending | | SHER Naamit; YOUNG Victor
M.; McNAUGHTON Alyn;
WILDING Ian; BAKHSHAEE
Massoud |
18
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | | | Status | | Inventor |
31577 | | USA
CIP | | 17-Nov-2000
60/248,582 | | | | 23-Feb-2006
11/359,513 | | 18 October 2011
8,039,261 | | 3182.0380000 | | Granted | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
BANGIO Livnat; PELED Michael |
37180 | | PCT | | 23-Feb-2006
11/359,513 | | | | 22-Feb-2007
IL2007/000242 | | Publ. Date: 30-Aug-2007
Publ. #: WO2007/096882 | | | | Expired | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
44720 | | USA
NP | | 17-Nov-2000
60/248,582 | | 20-Aug-2008 | | 22-Feb-2007
12/224,178 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
BANGIO Livnat; PELED Michael |
44708 | | Europe
NP | | 23-Feb-2006
11/359,513 | | 28-Aug-2008 | | 22-Feb-2007
07713267.8 | | | | | | Pending | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
[* * *] | | | | | | | | | | | | | | | | |
44709 | | Israel
NP | | 23-Feb-2006
11/359,513 | | 19-Aug-2008 | | 22-Feb-2007
193554 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
[* * *] | | | | | | | | | | | | | | | | |
44711 | | Canada
NP | | 23-Feb-2006
11/359,513 | | 20-Aug-2008 | | 22-Feb-2007
2,638,829 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
19
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
44712 | | Australia
NP | | 23-Feb-2006
11/359,513 | | 23-Sep-2008 | | 22-Feb-2007
2007219088 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
44713 | | Japan
NP | | 23-Feb-2006
11/359,513 | | 25-Aug-2008 | | 22-Feb-2007
2008-555946 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
44714 | | China
NP | | 23-Feb-2006
11/359,513 | | 21-Oct-2008 | | 22-Feb-2007
200780014285.2 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
44715 | | Republic of Korea
NP | | 23-Feb-2006
11/359,513 | | 22-Sep-2008 | | 22-Feb-2007
2008-7023144 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
44716 | | Mexico
NP | | 23-Feb-2006
11/359,513 | | 22-Aug-2008 | | 22-Feb-2007
MX/a/2008/010859 | | | | | | Abandoned | | HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
33794 | | USA CIP | | 09-Jul-2004
60/586,219 | | | | 09-Jan-2007
11/650,973 | | 05-Oct-2010
7,807,847 | | 3182.0200001 | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
49396 | | USA DIV | | 09-Jul-2004
60/586,219 | | 24-Aug-2010 | | 09-Jan-2007
12/861,921 | | 28-Feb 2012
8,124,800 | | 3182.0200002 | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
20
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
52800 | | USA DIV | | 09-Jul-2004
60/586,219 | | May 24, 2012 | | January 26, 2012
13/358,573 | | | | 3182.0200003 | | Pending | | HALPERIN Gideon;
KOVALEVSKI |
| | USA CIP | | 09-Jul-2004
60/586,219 | | | | Nov. 9, 2012
13/672,811 | | | | 3182.0200004 | | Pending | | HALPERIN Gideon;
KOVALEVSKI |
| | US CON | | 09-Jul-2004
60/586,219 | | | | Dec. 10, 2012
13/709,198 | | | | 3182.0200005 | | Pending | | HALPERIN Gideon;
KOVALEVSKI |
| | | | | | | | | | | | | | | | |
IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
43029 | | PCT | | 09-Jan-2007
11/650,973 | | | | 02-Jan-2008
IL2008/000013 | | Publ. Date: 17-Jul-2008
Publ. #: WO2008/084472 | | | | Expired | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46756 | | South Africa
NP | | 09-Jan-2007
11/650,973 | | | | 02-Jan-2008
2009/05601 | | 26-May-2010
2009/05601 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46755 | | New Zealand
NP | | 09-Jan-2007
11/650,973 | | 07-Aug-2009 | | 02-Jan-2008
578947 | | 4-Dec 2011
578947 | | 3182.020NZ01 | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
51026 | | New Zealand
DIV | | 09-Jan-2007
11/650,973 | | 15-Jun-2011 | | 02-Jan-2008
593529 | | | | 3182.020NZ11 | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
[* * *] | | | | | | | | | | | | | | | | |
21
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
46754 | | Australia
NP | | 09-Jan-2007
11/650,973 | | 07-Aug-2009 | | 02-Jan-2008
2008204238 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46753 | | Mexico
NP | | 09-Jan-2007
11/650,973 | | 09-Jul-2009 | | 02-Jan-2008
MX/a/2009/007422 | | 9-Jan 2012
294470 | | | | Granted | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
[* * *] | | | | | | | | | | | | | | | | |
46751 | | Israel
NP | | 09-Jan-2007
11/650,973 | | 09-Jul-2009 | | 02-Jan-2008
199792 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46750 | | China
NP | | 09-Jan-2007
11/650,973 | | 31-Aug-2009 | | 02-Jan-2008
200880006707.6 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46749 | | Republic of Korea
NP | | 09-Jan-2007
11/650,973 | | 27-Jul-2009 | | 02-Jan-2008
2009-7015780 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46748 | | Japan
NP | | 09-Jan-2007
11/650,973 | | 09-Jul-2009 | | 02-Jan-2008
2009-545295 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46747 | | Canada
NP | | 09-Jan-2007
11/650,973 | | 06-Jul-2009 | | 02-Jan-2008
2,674,902 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
46746 | | Europe
NP | | 09-Jan-2007
11/650,973 | | 07-Aug-2009 | | 02-Jan-2008
08700247.3 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
| | Europe
Div | | 09-Jan-2007
11/650,973 | | July 27, 2012 | | 02-Jan-2008
EP 12178298.1 | | | | 3182.020EP11 | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
48328 | | Hong Kong
NP | | | | 16-Mar-2010 | | 02-Jan-2008
10102729.2 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti |
22
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
|
METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
50375 | | PCT | | 05-Jan-2010
61/282,228 | | | | 05-Jan-2011
IL2011/000007 | | Publ. Date: 14-Jul-2011
Publ. #: WO2011/083464 | | | | Expired | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
| | US NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.0310002 | | Pending | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
| | EP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.031EP02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
| | IL | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.031IL02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
[* * *] | | | | | | | | | | | | | | | | |
| | JP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.031JP02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
23
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | MX | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.031MX02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | Canada | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.031CA02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
| | Au | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.031AU02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael |
| | | | | | | | | | | | | | | | |
COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
50376 | | PCT | | 05-Jan-2010
61/282,228 | | | | 05-Jan-2011
IL2011/000009 | | Publ. Date: 14-Jul-2011
Publ. #: WO2011/083466 | | 3182.032PC02 | | Expired | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
24
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
| | US NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.0320002 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
| | EU NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.032EP02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
| | IL NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.032IL02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
[* * *] | | | | | | | | | | | | | | | | |
| | JP NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.032JP02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
| | KR NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.032KR02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
| | MX NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.032MX02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | CA NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.032CA02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
| | AU NP | | 05-Jan-2010
61/282,228 | | June 2012 | | 05-Jan-2011 | | | | 3182.032AU02 | | Pending | | BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J. |
25
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | | | Status | | Inventor |
32516 | | USA
CIP | | 27-May-2003
10/445,347 | | | | 28-Sep-2006
11/528,657 | | 01-Dec-2009
7,625,882 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak |
46643 | | USA
DIV | | 27-May-2003
10/445,347 | | 14-Oct-2009 | | 28-Sep-2006
12/588,371 | | 05-Jul-2011
7,973,023 | | | | Granted | | HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak |
50968 | | USA
CON | | 27-May-2003
10/445,347 | | 13-Apr-2011 | | 28-Sep-2006
13/085,542 | | | | | | Pending | | HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak |
| | | | | | | | | | | | | | | | |
AN IMMUNOLOGICAL AND ORAL TOLERANCE-INDUCING COMPOSITION AND USE THEREOF FOR THE PREVENTION AND/OR FOR THE TREATMENT OF ATHEROSCLEROSIS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
00/21414 | | Israel
Basic | | | | | | 04-Oct-1998
126447 | | 30-Dec-2004
126447 | | | | Granted | | HARATS Dror; SHOENFELD
Yehuda; GEORGE Jacob |
26
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
A COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
01/21558 | | PCT | | 04-Oct-1998
126447 | | 01-Apr-2001 | | 30-Sep-1999
IL99/00519 | | Publ. Date: 13-Apr-2000
Publ. #: WO00/20019 | | | | Expired | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/21884 | | Europe
NP | | 04-Oct-1998
126447 | | | | 30-Sep-1999
99970026.3 | | 14-May-2003
1126867 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/21886 | | Canada
NP | | 04-Oct-1998
126447 | | | | 30-Sep-1999
2,345,445 | | 24-Aug-2010
2,345,445 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/21887 | | Australia
NP | | 04-Oct-1998
126447 | | | | 30-Sep-1999
59966/99 | | 28-Aug-2003
760582 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/21888 | | China
NP | | 04-Oct-1998
126447 | | 04-Apr-2001 | | 30-Sep-1999
99814030.9 | | 24-Nov-2004
ZL99814030.9 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
02/23904 | | Hong Kong
NP | | 04-Oct-1998
126447 | | 19-Jul-2002 | | 30-Sep-1999
02105365.4 | | 18-Nov-2005
HK1043743 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
28590 | | China
DIV | | 04-Oct-1998
126447 | | 23-Sep-2004 | | 30-Sep-1999
200410011940.7 | | 05-Nov-2008
ZL200410011940.7 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
30562 | | Hong Kong
DIV | | 04-Oct-1998
126447 | | 28-Sep-2005 | | 30-Sep-1999
05108561.7 | | 21-Aug-2009
HK1076600 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/21889 | | Singapore
NP | | 04-Oct-1998
126447 | | | | 30-Sep-1999
200101998-3 | | 30-Apr-2003
80182 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
27
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
01/21890 | | Japan
NP | | 04-Oct-1998
126447 | | | | 30-Sep-1999
2000-573378 | | | | | | Pending | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/21891 | | Hungary
NP | | 04-Oct-1998
126447 | | 30-Sep-1999 | | 30-Sep-1999
P0104410 | | | | | | Pending | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
[* * *] | | | | | | | | | | | | | | | | |
01/21893 | | Republic of Korea
NP | | 04-Oct-1998
126447 | | | | 30-Sep-1999
2001-7004285 | | 02-Feb-2007
680707 | | | | Granted | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/21885 | | USA
NP | | 04-Oct-1998
126447 | | 30-Mar-2001 | | 30-Sep-1999
09/806,400 | | | | | | Abandoned | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
01/22498 | | USA
CON | | 04-Oct-1998
126447 | | 04-Sep-2001 | | 30-Sep-1999
09/944,592 | | | | | | Abandoned | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob |
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
28919 | | USA
CIP | | 04-Oct-1998
126447 | | | | 15-Apr-2005
11/106,665 | | | | | | Abandoned | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva |
28
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest
Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
26038 | | USA
CIP | | 22-Nov-2000
60/252,574 | | | | 27-May-2003
10/445,347 | | 04-Jan-2005
6,838,452 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
27041 | | USA
DIV | | 24-Nov-2000
60/252,574 | | 24-Nov-2003 | | 27-May-2003
10/718,596 | | 06-Mar-2007
7,186,704 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
29890 | | USA
DIV | | 24-Nov-2000
60/252,574 | | 19-Jul-2005 | | 27-May-2003
11/183,884 | | 17-Mar-2009
7,504,388 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
45347 | | USA
DIV | | 24-Nov-2000
60/252,574 | | 17-Feb-2009 | | 27-May-2003
12/371,930 | | 22-Feb-2011
7,893,291 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
50439 | | USA
CON | | 24-Nov-2000
60/252,574 | | 06-Jan-2011 | | 27-May-2003
12/985,365 | | 17 April
20128,158,611 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
53355 | | USA
CON | | 24-Nov-2000
60/252,574 | | March 27, 2012 | | 27-May-2003
13/431,262 | | | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
29
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
27909 | | PCT | | 27-May-2003
10/445,347 | | | | 27-May-2004
IL2004/000453 | | Publ. Date: 09-Dec-2004
Publ. #: WO2004/106486 | | | | Expired | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon |
31532 | | USA
NP | | 27-May-2003
10/445,347 | | 25-Apr-2008 | | 27-May-2004
10/567,543 | | 08-Mar-2011
7,902,176 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30958 | | Mexico
NP | | 27-May-2003
10/445,347 | | 25-Nov-2005 | | 27-May-2004
pa/A/2005/012784 | | 14-Oct-2008
261341 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon |
[* * *] | | | | | | | | | | | | | | | | |
30947 | | Europe
NP | | 27-May-2003
10/445,347 | | 07-Dec-2005 | | 27-May-2004
04735088.9 | | | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
32340 | | Hong Kong
NP | | 27-May-2003
10/445,347 | | 03-Aug-2006 | | 27-May-2004
06108608.1 | | | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30948 | | Japan
NP | | 27-May-2003
10/445,347 | | 30-Nov-2005 | | 27-May-2004
2006-531006 | | | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
[* * *] | | | | | | | | | | | | | | | | |
30949 | | Canada
NP | | 27-May-2003
10/445,347 | | 28-Nov-2005 | | 27-May-2004
2,527,483 | | | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30950 | | China
NP | | 27-May-2003
10/445,347 | | 01-Nov-2005 | | 27-May-2004
200480021217.5 | | 22-Dec-2010
ZL200480021217.5 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
49865 | | China
DIV | | 27-May-2003
10/445,347 | | 25-Oct-2010 | | 27-May-2004
201010537971.1 | | | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30951 | | Australia
NP | | 27-May-2003
10/445,347 | | 13-Dec-2005 | | 27-May-2004
2004243695 | | 17-Mar-2011
2004243695 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30952 | | Republic of Korea
NP | | 27-May-2003
10/445,347 | | 28-Nov-2005 | | 27-May-2004
2005-7022741 | | 3-Nov 2011
1081977 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
50809 | | Republic of Korea
DIV | | 27-May-2003
10/445,347 | | 18-Feb-2011 | | 27-May-2004
2011-7003840 | | 23 Feb 2012
10-1122160 | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30953 | | New Zealand
NP | | 27-May-2003
10/445,347 | | 01-Dec-2005 | | 27-May-2004
544285 | | 12-Mar-2009
544285 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30954 | | South Africa
NP | | 27-May-2003
10/445,347 | | 01-Dec-2005 | | 27-May-2004
2005/09929 | | 27-Dec-2006
2005/9929 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
30955 | | India
NP | | 27-May-2003
10/445,347 | | 27-Dec-2005 | | 27-May-2004
3555/CHENP/2005 | | 26-Mar-2009
232654 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
[* * *] | | | | | | | | | | | | | | | | |
31
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
30957 | | Russian Federation
NP | | 27-May-2003
10/445,347 | | 01-Dec-2005 | | 27-May-2004
2005140666 | | 27-Jul-2009
2362567 | | | | Granted | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
46052 | | Russian Federation
DIV | | 27-May-2003
10/445,347 | | 06-Apr-2009 | | 27-May-2004
2009112686 | | | | | | Pending | | HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva |
OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
46530 | | PCT | | 08-Oct-2008
61/103,571 | | | | 01-Oct-2009
IL2009/000949 | | Publ. Date: 15-Apr-2010
Publ. #: WO2010/041242 | | | | Expired | | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez |
50053 | | USA
NP | | 08-Oct-2008
61/103,571 | | 06-Apr-2011 | | 01-Oct-2009
13/122,766 | | | | | | Pending | | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez |
50054 | | Europe
NP | | 08-Oct-2008
61/103,571 | | 20-Apr-2011 | | 01-Oct-2009
09818874.1 | | | | | | Pending | | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez |
32
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
50055 | | Israel
NP | | 08-Oct-2008
61/103,571 | | 05-Apr-2011 | | 01-Oct-2009
212153 | | | | | | Pending | | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez |
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I-DERIVED PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
31865 | | PCT | | 15-Apr-2005
60/671,500 | | | | 11-Apr-2006
IL2006/000467 | | Publ. Date: 19-Oct-2006
Publ. #: WO2006/109312 | | | | Expired | | YACOV Niva; BREITBART Eyal |
41853 | | Europe
NP | | 15-Apr-2005
60/671,500 | | 24-Oct-2007 | | 11-Apr-2006
06728268.1 | | | | | | Abandoned | | YACOV Niva; BREITBART Eyal |
41854 | | USA
NP | | 15-Apr-2005
60/671,500 | | 10-Oct-2007 | | 11-Apr-2006
11/918,141 | | | | | | Abandoned | | YACOV Niva; BREITBART Eyal |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
NOVEL DERIVATIVES OF OXIDIZED PHOSPHOLIPIDS
33
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
| | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
|
| OXIDIZED LIPID COMPOUNDS AND USES THEREOF |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
45018 | | PCT | | 06-Nov-2008
61/193,220 | | | | 05-Nov-2009
IL2009/001049 | | Publ. Date: 14-May-2010
Publ. #: WO2010/052718 | | | | Expired | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
50603 | | USA
NP | | 06-Nov-2008
61/193,220 | | 05-May-2011 | | 05-Nov-2009
13/127,717 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
[* * *] | | | | | | | | | | | | | | | | |
50605 | | Europe
NP | | 06-Nov-2008
61/193,220 | | 16-May-2011 | | 05-Nov-2009
09824498.1 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
51983 | | Hong Kong
NP | | | | | | 05-Nov-2009 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
34
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
50606 | | Canada
NP | | 06-Nov-2008
61/193,220 | | 13-Apr-2011 | | 05-Nov-2009
2,740,726 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
[* * *] | | | | | | | | | | | | | | | | |
50608 | | Australia
NP | | 06-Nov-2008
61/193,220 | | 15-Apr-2011 | | 05-Nov-2009
2009312355 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
50609 | | New Zealand
NP | | 06-Nov-2008
61/193,220 | | 19-Apr-2011 | | 05-Nov-2009
592357 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
[* * *] | | | | | | | | | | | | | | | | |
50611 | | Japan
NP | | 06-Nov-2008
61/193,220 | | 06-May-2011 | | 05-Nov-2009 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
50612 | | Republic of Korea
NP | | 06-Nov-2008
61/193,220 | | 02-Jun-2011 | | 05-Nov-2009
2011-7012700 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
35
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
50613 | | Mexico
NP | | 06-Nov-2008
61/193,220 | | 04-May-2011 | | 05-Nov-2009
MX/a/2011/004773 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
50614 | | Russian Federation
NP | | 06-Nov-2008
61/193,220 | | 06-Jun-2011 | | 05-Nov-2009
2011122729 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
50615 | | China
NP | | 06-Nov-2008
61/193,220 | | 30-Jun-2011 | | 05-Nov-2009
200980153378.2 | | | | | | Pending | | HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez |
ENDOTHELIAL-SPECIFIC APOPTOSIS INDUCED BY AN ADENOVIRAL VECTOR CONTAINING A CHIMERIC RECEPTOR DRIVEN BY A TISSUE SPECIFIC PROMOTER
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date Patent No. | | SKGF Ref | | Status | | Inventor |
| | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
|
| POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY |
| | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date Patent No. | | SKGF Ref | | Status | | Inventor |
02/23346 | | PCT | | 19-Oct-2001
60/330,118 | | | | 01-May-2002
IL02/00339 | | Publ. Date: 24-Apr-2003 Publ. #: WO03/033514 | | | | Expired | | HARATS Dror;
GREENBERGER Shoshana |
27526 | | USA
NP | | 19-Oct-2001
60/330,118 | | 12-Apr-2004 | | 01-May-2002
10/490,746 | | 08-Sep-2009 7,585,666 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
36
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
44506 | | USA
DIV | | 19-Oct-2001
60/330,118 | | 08-Aug-2008 | | 01-May-2002
12/222,439 | | 02-Aug-2011 7,989,427 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
51506 | | USA
DIV | | 19-Oct-2001
60/330,118 | | 20-Jun-2011 | | 01-May-2002
13/163,767 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27527 | | Europe
NP | | 19-Oct-2001
60/330,118 | | 21-Apr-2004 | | 01-May-2002
02801473.6 | | 22-Sep-2010 1436313 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
29028 | | Hong Kong
NP | | 19-Oct-2001
60/330,118 | | 06-Jan-2005 | | 01-May-2002
05100081.5 | | 01-Apr-2011 HK1067641 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
49785 | | Europe
DIV | | 19-Oct-2001
60/330,118 | | 17-Sep-2010 | | 01-May-2002
EP10177257.2 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
47553 | | Europe
DIV | | 19-Oct-2001
60/330,118 | | 18-Nov-2009 | | 01-May-2002
09176343.3 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
49931 | | Hong Kong
DIV | | 19-Oct-2001
60/330,118 | | 10-Dec-2010 | | 01-May-2002
10111522.2 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
51004 | | Hong Kong
DIV | | 19-Oct-2001
60/330,118 | | 27-Apr-2011 | | 01-May-2002
11104228.3 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27528 | | Japan
NP | | 19-Oct-2001
60/330,118 | | 16-Apr-2004 | | 01-May-2002
2003-536253 | | 22-Aug-2008 4,173,446 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
37
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
27529 | | Republic of Korea
NP | | 19-Oct-2001
60/330,118 | | 17-Apr-2004 | | 01-May-2002
2004-7005720 | | 24-Oct-2008 866117 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27530 | | India
NP | | 19-Oct-2001
60/330,118 | | 19-Apr-2004 | | 01-May-2002
801/CHENP/2004 | | 26-Dec-2008 226357 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27531 | | China
NP | | 19-Oct-2001
60/330,118 | | 09-Jun-2004 | | 01-May-2002
02824547.4 | | 01-Jul-2009 ZL02824547.4 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
46077 | | China
DIV | | 19-Oct-2001
60/330,118 | | 27-Apr-2009 | | 01-May-2002
200910137707.6 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27532 | | Singapore
NP | | 19-Oct-2001
60/330,118 | | 16-Apr-2004 | | 01-May-2002
200402237-2 | | 31-May-2006 103725 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27533 | | Canada
NP | | 19-Oct-2001
60/330,118 | | 16-Apr-2004 | | 01-May-2002
2,463,816 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27534 | | Mexico
NP | | 19-Oct-2001
60/330,118 | | 19-Apr-2004 | | 01-May-2002
PA/a/2004/003514 | | 12-Nov-2010 280956 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
[* * *] | | | | | | | | | | | | | | | | |
27535 | | Australia
NP | | 19-Oct-2001
60/330,118 | | 20-Apr-2004 | | 01-May-2002
2002307793 | | 17-May-2007 2002307793 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27536 | | New Zealand
NP | | 19-Oct-2001
60/330,118 | | 16-Apr-2004 | | 01-May-2002
532348 | | 12-Oct-2006 532348 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
27537 | | South Africa
NP | | 19-Oct-2001
60/330,118 | | 08-Apr-2004 | | 01-May-2002
2004/2756 | | 31-May-2006 2004/02756 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal |
38
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
USING A MINI-GENE CONSTRUCT (3X-PPR-1) FOR ENDOTHELIAL CELLS SPECIFIC GENE THERAPY. IMPLICATIONS IN CARDIOVASCULAR, CANCER AND WOUND HEALING
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
01/22752 | | PCT | | 17-Nov-2000
60/248,582 | | | | 15-Nov-2001
IL01/01059 | | Publ. Date: 23-May-2002
Publ. #: WO02/40629 | | | | Expired | | HARATS Dror |
26025 | | Europe
NP | | 17-Nov-2000
60/248,582 | | 15-May-2003 | | 15-Nov-2001
01996590.4 | | 20-Jan-2010
1443970 | | | | Granted | | HARATS Dror; BLOOM Nira |
29027 | | Hong Kong
NP | | 17-Nov-2000
60/248,582 | | 12-Jan-2005 | | 15-Nov-2001
05100240.3 | | 20-Aug-2010
HK1068057 | | | | Granted | | HARATS Dror; BLOOM Nira |
47088 | | Europe
DIV | | 17-Nov-2000
60/248,582 | | 04-Nov-2009 | | 15-Nov-2001
09174998.6 | | | | | | Pending | | HARATS Dror; BLOOM Nira |
49806 | | Europe
DIV | | 17-Nov-2000
60/248,582 | | 01-Oct-2010 | | 15-Nov-2001
EP10185193.9 | | | | | | Pending | | HARATS Dror; BLOOM Nira |
49498 | | Hong Kong
DIV | | 17-Nov-2000
60/248,582 | | 13-Oct-2010 | | 15-Nov-2001
10109698.4 | | | | | | Pending | | HARATS Dror; BLOOM Nira |
39
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
52630 | | Hong Kong
DIV | | 17-Nov-2000
60/248,582 | | 2-Dec-2011 | | 15-Nov-2001
11113094.5 | | | | 3182.034HK21 | | Pending | | HARATS Dror; BLOOM Nira |
26026 | | Israel
NP | | 17-Nov-2000
60/248,582 | | 15-May-2003 | | 15-Nov-2001
155940 | | 30-Mar-2009
155940 | | | | Granted | | HARATS Dror; BLOOM Nira |
26027 | | India
NP | | 17-Nov-2000
60/248,582 | | 14-May-2003 | | 15-Nov-2001
743/CHENP/2003 | | 20-Nov-2007
211599 | | | | Granted | | HARATS Dror; BLOOM Nira |
26028 | | USA
NP | | 17-Nov-2000
60/248,582 | | 16-May-2003 | | 15-Nov-2001
10/416,917 | | | | | | Abandoned | | HARATS Dror |
26029 | | Canada
NP | | 17-Nov-2000
60/248,582 | | 15-May-2003 | | 15-Nov-2001
2,429,342 | | | | | | Pending | | HARATS Dror; BLOOM Nira |
26030 | | Australia
NP | | 17-Nov-2000
60/248,582 | | 15-May-2003 | | 15-Nov-2001
2002224002 | | 26-Jul-2007
2002224002 | | | | Abandoned | | HARATS Dror |
28653 | | Australia
DIV | | 17-Nov-2000
60/248,582 | | 01-Dec-2004 | | 15-Nov-2001
2003222427 | | 09-Sep-2010
2003222427 | | | | Granted | | HARATS Dror; BREITBART
Eyal; BLOOM Nira |
49098 | | Australia
DIV | | 15-Nov-2001
2002224002 | | 25-Jun-2010 | | 15-Nov-2001
2010202660 | | 1-Dec 2011
2010202660 | | | | Granted | | HARATS Dror; BREITBART
Eyal; BLOOM Nira |
26031 | | Japan
NP | | 17-Nov-2000
60/248,582 | | 16-May-2003 | | 15-Nov-2001
2002-543626 | | 16-Jan-2009
4,243,653 | | | | Granted | | HARATS Dror; BLOOM Nira |
26032 | | China
NP | | 17-Nov-2000
60/248,582 | | 16-Jul-2003 | | 15-Nov-2001
01822075.4 | | 04-Feb-2009
ZL0182275.4 | | | | Granted | | HARATS Dror; BLOOM Nira |
40
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | |
26033 | | Republic of Korea
NP | | 17-Nov-2000
60/248,582 | | 17-May-2003 | | 15-Nov-2001
2003-7006728 | | 14-Nov-2008
869814 | | Granted | | HARATS Dror |
44105 | | Republic of Korea
DIV | | 17-Nov-2000
60/248,582 | | 28-Jul-2008 | | 15-Nov-2001
2008-7018598 | | 10-Sep-2009
917854 | | Granted | | HARATS Dror; BLOOM Nira |
26034 | | Mexico
NP | | 17-Nov-2000
60/248,582 | | 16-May-2003 | | 15-Nov-2001
PA/a/2003/004325 | | 15-Aug-2008
259670 | | Granted | | HARATS Dror |
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
28918 | | USA CIP | | 04-Oct-1998
126447 | | | | 17-Nov-2004
10/989,724 | | | | | | Abandoned | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva |
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
30236 | | PCT | | 17-Nov-2004
10/989,724 | | | | 25-Sep-2005
IL2005/001022 | | Publ. Date:
26-May-2006 Publ. #: |WO2006/054281 | | | | Expired | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva |
39233 | | Europe NP | | 17-Nov-2004
10/989,724 | | 13-Jun-2007 | | 25-Sep-2005
05788473.6 | | | | | | Abandoned | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva |
42004 | | Hong Kong NP | | 17-Nov-2004
10/989,724 | | | | 12-Sep-2007
07109873.6 | | | | | | Abandoned | | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva |
41
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS
| | | | | | | | | | | | | | | | |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
28376 | | USA
CIP | | 17-Nov-2000
60/248,582 | | | | 14-Nov-2004
10/988,487 | | 6-Dec 2011
8,071,740 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
50225 | | USA
DIV | | 17-Nov-2000
60/248,582 | | 01-Feb-2011 | | 14-Nov-2004
13/018,447 | | 26-June 2012
8,206,743 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
50927 | | USA
DIV | | 17-Nov-2000
60/248,582 | | 02-May-2011 | | 14-Nov-2004
13/098,512 | | | | | | Aban | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
47407 | | USA
DIV | | 17-Nov-2000
60/248,582 | | 13-Nov-2009 | | 14-Nov-2004
12/591,252 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
60001 | | USA
Con | | 17-Nov-2000
60/248,582 | | 13-July 2012 | | 14-Nov-2004
13/549,355 | | | | 3182.0370004 | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
30269 | | PCT | | 14-Nov-2004 | | | | 14-Nov-2005 | | Publ. Date: 18-May-2006 | | | | Expired | | HARATS Dror;
GREENBERGER Shoshana |
42
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | |
| | | | 10/988,487 | | | | IL2005/001195 | | Publ. #: WO2006/051545 | | | | |
[* * *] | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | |
47087 | | Europe
DIV | | 14-Nov-2004
10/988,487 | | 28-Aug-2009 | | 14-Nov-2005
09168899.4 | | 2 Nov 2011
2174668 | | Grnated | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
49224 | | Hong Kong
DIV | | | | 12-Oct-2010 | | 14-Nov-2005
10109638.7 | | 15 June 2012
HK1143078 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
49804 | | Europe
DIV | | 14-Nov-2004
10/988,487 | | 01-Oct-2010 | | 14-Nov-2005
EP10185195.4 | | 26 Sep 2012
2301586 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
49805 | | Europe
DIV | | 14-Nov-2004
10/988,487 | | 30-Sep-2010 | | 14-Nov-2005
EP10184033.8 | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
39318 | | Australia
NP | | 14-Nov-2004
10/988,487 | | 08-Jun-2007 | | 14-Nov-2005
2005303385 | | | | Allowed | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
51825 | | Australia
DIV | | 14-Nov-2004
10/988,487 | | | | 14-Nov-2005 | | 28 June 2012
2011205076 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
53691 | | Australia | | 14-Nov-2004 | | 15 June 2012 | | 14-Nov-2005 | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana; |
43
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | |
| | DIV | | 10/988,487 | | | | 2012203578 | | | | | | BREITBART Eyal; BANGIO
Livnat; PELED Michael |
39323 | | New Zealand
NP | | 14-Nov-2004
10/988,487 | | 05-Jun-2007 | | 14-Nov-2005
555612 | | 08-Apr-2010
555612 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
47297 | | New Zealand
DIV | | 14-Nov-2004
10/988,487 | | 09-Oct-2009 | | 14-Nov-2005
580289 | | 05-Apr-2011
580289 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
39324 | | South Africa
NP | | 14-Nov-2004
10/988,487 | | 05-Jun-2007 | | 14-Nov-2005
2007/04687 | | 31-Dec-2008
2007/04687 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat |
[* * *] | | | | | | | | | | | | | | |
50629 | | Singapore
DIV | | 14-Nov-2004
10/988,487 | | 11-Apr-2011 | | 14-Nov-2005
201102612-7 | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat |
39315 | | Israel
NP | | 14-Nov-2004
10/988,487 | | 14-May-2007 | | 14-Nov-2005
183187 | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
50104 | | Israel
DIV | | 14-Nov-2004
10/988,487 | | 31-Oct-2010 | | 14-Nov-2005
209034 | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat |
[* * *] | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | |
44
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
39317 | | Canada
NP | | 14-Nov-2004
10/988,487 | | 17-May-2007 | | 14-Nov-2005
2,587,469 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
39319 | | Japan
NP | | 14-Nov-2004
10/988,487 | | 14-May-2007 | | 14-Nov-2005
2007-540833 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
52137 | | Japan
Div | | 14-Nov-2004
10/988,487 | | Sep 2011 | | 14-Nov-2005
2011-191492 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
39320 | | China
NP | | 14-Nov-2004
10/988,487 | | 13-Aug-2007 | | 14-Nov-2005
200580046412.8 | | | | | | Aban | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
39321 | | Republic
of KoreaNP | | 14-Nov-2004
10/988,487 | | 14-Jun-2007 | | 14-Nov-2005
2007-7013464 | | | | | | Pending | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael |
39322 | | Mexico
NP | | 14-Nov-2004
10/988,487 | | 11-May-2007 | | 14-Nov-2005
MX/a/2007/005783 | | 8 May 2012
299008 | | | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat |
52598 | | Mexico
Div | | 14-Nov-2004
10/988,487 | | | | 14-Nov-2005 | | 4 Sep 2012
303042 | | 3182.037MX11 | | Granted | | HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat |
[* * *] | | | | | | | | | | | | | | | | |
45
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
Method for treating vascular inflammation and psoriasis |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Treatment Of Inflammation |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
[* * *] | | | | | | | | | | | | | | | | |
53305 | | PCT | | 12 Dec 2011
61/569,545 and 12 Dec 2011 61/569,481 | | | | 11 Dec 2012
PCT/US2012/068995 | | | | 3182.014PC01 | | Pending | | MENDEL, Itzhak;
FEIGE, Erez; YACOV, Niva; PROPHETE-MEIRAN, Oshrat;
BREITBART, Eyal; SALEM, Yaniv |
46
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | | | |
Treatment Methods Using Adenovirus |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
[* * *] | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
TARGETED GENE EXPRESSION USING PREPROENDOTHELIN-1 PROMOTERS |
Our
Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
N/A | | USA CIP | | 03-Mar-1994
08/254,015 | | | | 28-Feb-1995
08395742 | | 05-May-1998
5747340 | | Originally assinged to Syntex
USA. Licensed to VBL | | Granted | | HARATS Dror;
KURIHARA Hiroki; NANETTE BELLONI Paula; SIGAL
Charles Elliott |
| | | | | | | | | | | | | | | | |
METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS |
Our Ref | | Country | | Earliest Priority | | Entry Date | | Filing Date
Application No. | | Issue Date
Patent No. | | SKGF Ref | | Status | | Inventor |
N/A | | PCT | | 08-Dec-2009
61/283,696 | | | | 07-Dec-2010
US2010/059204 | | Publ. Date: 16-Jun-2011
Publ. #: WO/2011/071859 | | As of June 2012, the applicant is also VBL | | Pending | | KOLESNICK, Richard, N.
STANCEVIC, Branka; SADELAIN, Michel; FUKS, Zvi; VARDA-BLOOM, Nira; HARATS, Dror; |
47
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | |
Trademark: VBL therapeutics & logo |
Our Ref Client Ref | | Country | | Class | | Earliest
Priority | | Filing Date
Application No. | | Registration Date
Registration No. | | SKGF Ref | | Status |
47638 | | Europe | | 5, 42 & 44 | | | | 03-Dec-2009
008730541 | | 02-Jun-2010
008730541 | | | | Registered |
Trademark: VASCULAR BIOGENICS |
Our Ref Client Ref | | Country | | Class | | Earliest
Priority | | Filing Date
Application No. | | Registration Date
Registration No. | | SKGF Ref | | Status |
42092 | | Israel | | 42 | | | | 23-Aug-2007
203346 | | 06-May-2009
203346 | | | | Registered |
43074 | | USA
(Paris) | | 42 | | 23-Aug-2007
203346 | | 14-Feb-2008
77/397,305 | | 22-Jun-2010
3,805,239 | | | | Registered |
43075 | | Europe
(Paris) | | 5, 42 & 44 | | 23-Aug-2007
203346 | | 18-Feb-2008
006675599 | | 20-Feb-2009
006675599 | | | | Registered |
48
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
Trademark: VBL VASCULAR BIOGENICS LTD. & Device
| | | | | | | | | | | | | | |
Our Ref Client Ref | | Country | | Class | | Earliest
Priority | | Filing Date
Application No. | | Registration Date
Registration No. | | SKGF Ref | | Status |
42199 | | Israel | | 42 | | | | 09-Sep-2007
203748 | | 10-May-2009
203748 | | | | Registered |
43602 | | USA
(Paris) | | 42 | | 09-Sep-2007
203748 | | 03-Mar-2008
77/411,204 | | 22-Jun-2010
3,805,245 | | | | Registered |
43603 | | Europe
(Paris) | | 42 | | 09-Sep-2007
203748 | | 04-Mar-2008
006721823 | | 04-Sep-2009
006721823 | | | | Registered |
Trademark: VTS |
Our Ref Client Ref | | Country | | Class | | Earliest
Priority | | Filing Date
Application No. | | Registration Date
Registration No. | | SKGF Ref | | Status |
42198 | | Israel | | 5 | | | | 09-Sep-2007
203747 | | 06-May-2009
203747 | | | | Registered |
43600 | | USA
(Paris) | | 5 | | 09-Sep-2007
203747 | | 03-Mar-2008
77/411,151 | | 20-Oct-2009
3,697,519 | | | | Registered |
43601 | | Europe
(Paris) | | 5 | | 09-Sep-2007
203747 | | 04-Mar-2008
006721484 | | 20-Feb-2009
006721484 | | | | Registered |
49
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
Trademark: VASCULAR TARGETING SYSTEM VTS
| | | | | | | | | | | | | | |
Our Ref Client Ref | | Country | | Class | | Earliest
Priority | | Filing Date
Application No. | | Registration Date
Registration No. | | SKGF Ref | | Status |
41864 | | Israel | | 5 | | | | 23-Aug-2007
203345 | | 08-Sep-2009
203345 | | | | Registered |
43072 | | USA
(Paris) | | 5 | | 23-Aug-2007
203345 | | 14-Feb-2008
77/397,328 | | 18-May-2010
3,789,108 | | | | Registered |
43073 | | Europe
(Paris) | | 5, 42 & 44 | | 23-Aug-2007
203345 | | 18-Feb-2008
006675896 | | 29-Jan-2009
006675896 | | | | Registered |
50
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
| | | | | | | | | | | | | | |
Trademark: VBL |
Our Ref Client Ref | | Country | | Class | | Earliest
Priority | | Filing Date
Application No. | | Registration Date
Registration No. | | SKGF Ref | | Status |
42093 | | Israel | | 42 | | | | 23-Aug-2007
203347 | | 22-Jan-2009
203347 | | | | Registered |
43076 | | USA
(Paris) | | 42 | | 23-Aug-2007
203347 | | 14-Feb-2008
77/397,293 | | 14-Jul-2009
3,653,176 | | | | Registered |
43077 | | Europe
(Paris) | | 5, 42 & 44 | | 23-Aug-2007
203347 | | 18-Feb-2008
006673263 | | 22-Jan-2009
006673263 | | | | Registered |
Trademark: VBL therapeutics & logo |
Our Ref Client Ref | | Country | | Class | | Earliest
Priority | | Filing Date
Application No. | | Registration Date
Registration No. | | SKGF Ref | | Status |
47612 | | Israel | | 42 | | | | 30-Nov-2009
225329 | | 07-Feb-2011
225329 | | | | Registered |
47639 | | USA
(Paris) | | 42 | | 30-Nov-2009
225329 | | 26-Apr-2010
85/023,397 | | 24-May-2011
3,964,829 | | | | Registered |
51
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
Domains: VBL
vascularbiogenics.com
vascularbiogenicsltd.com
vbl-therapeutics.com
vbltherapeutics.com
vbltx.com
vascularbiogenics.net
vbl.co.il
vblrx.com
vascular-biogenics.com
52
|
| Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *]. |
